^
Association details:
| Biomarker: | GSPT1 deletion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | ORM-5029 (HER2-targeted antibody-drug conjugate, HER3-targeted antibody-drug conjugate, GSPT1 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 3933: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer
Published date:
06/15/2022
Excerpt:
ORM-5029 treatment in the HER2-expressing cell lines showed 10-1000 fold superiority in potency...We evaluated ORM-5029 in several in vivo xenograft models and observed robust efficacy, following a single-dose treatment testing as low as 3 mg/kg. In the BT474 xenograft model, treatment with ORM-5029 demonstrated single-dose activity...In an HCC1569 xenograft model, tumor growth inhibition correlated with the degree and duration of GSPT1 depletion and changes in expression of previously described integrated stress response biomarker genes. ORM-5029 is currently in preclinical development as a potential first-in-class targeted protein degrader therapy with HER2-targeted delivery.
DOI:
10.1158/1538-7445.AM2022-3933
